Purpose: To report the complications and long-term results of laser-induced chorioretinal venous anastomosis in vein occlusions. Patients and Methods: Eight consecutive eyes, 3 with central retinal vein (CRVO) and 5 with branch retinal vein occlusion (BRVO), were observed for up to 5 years after attempted laser-induced chorioretinal venous anastomosis. Results: Successful chorioretinal venous anastomoses were created in 2 (25%) eyes. Patients had severe complications, including vitreous hemorrhage, choroidal neovascular membrane, choriovitreal neovascularization, rubeosis iridis and neovascular glaucoma. Conclusion: The utilization of a chorioretinal venous anastomosis by laser with proposed laser settings as a therapeutic modality should be further analyzed, and a careful long-term follow-up must be done to avoid vision-threatening complications.

Keywords:
Argon laser, Chorioretinal venous anastomosis, Central retinal vein occlusion, Branch retinal vein occlusion
1.
McAllister IL, Constable IJ: Laser-induced chorioretinal venous anostomosis for treatment of non-ischemic CRVO. Arch Ophthalmol 1995;113:456–462.
2.
Fekrat S, Goldberg MF, Finkelstein D: Laser-induced chorioretinal venous anastomosis for nonischemic central or branch vein occlusion. Arch Ophthalmol 1998;116:43–52.
3.
McAllister IL, Douglas JP, Constable IJ, Yu D: Laser-induced chorioretinal venous anastomosis for treatment of non-ischemic CRVO: Evaluation of the complications and their risk factors. Am J Ophthalmol 1998;126:219–229.
4.
Browning DJ, Roberg MH: Vitreous hemorrhage complicating laser-induced chorioretinal anastomosis for central retinal vein occlusion. Am J Ophthalmol 1996;122:588–589.
5.
Eccarius SG, Moran MJ, Slingsby JG: Choroidal neovascular membrane after laser-induced chorioretinal anastomosis. Am J Ophthalmol 1996;122:590–591.
6.
Luttrall J: Epiretinal membrane and traction retinal detachment complicating laser-induced chorioretinal venous anastomosis. Am J Ophthalmol 1997;123:698–699.
7.
Minturn J, Brown GC: Progression of non-ischemic central retinal vein obstruction to the ischemic variety. Ophthalmology 1986;93:1158–1162.
8.
Central Retinal Vein Occlusion Study Group: A randomized clinical trial of early panretinal photocoagulation for ischemic central retinal vein occlusion: The Central Vein Occlusion Study Group report. Ophthalmology 1995;102:1434–1444.
9.
Matsuhashi H, Mizutani H, Tamura M, Nakazawa M: A case of choroidovitreal neovascularization after unsuccessful laser chorioretinal venous anastomosis for central retinal vein occlusion. Nippon Ganka Gakkai Zasshi 2002;106:44–46.
10.
Lu N, Li Z, Sun X, Wang G, Zhang F, Peng X: VEGF expression in dog retina after chorioretinal venous anastomosis. Zhongkhua Yan Ke Za Zhi 2002;38:526–529.
11.
Leonard BC, Coupland SG, Kertes PJ, Bate R: Long-term follow-up of a modified technique for laser induced chorioretinal venous anastomosis in nonischemic central retinal vein occlusion. Ophthalmology 2003;110:948–995.
12.
Browning DJ, Antoszyk AN: Laser chorioretinal venous anastomosis for nonischemic central retinal vein occlusion. Ophthalmology 1998;105:670–679.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.